Von Hippel–Lindau (VHL): Symptoms, Testing and Care

Symptoms that should not wait for a routine appointment

For less dramatic changes, write down what happened, when it started, whether it is worsening, and how it affects ordinary activities. When you call, ask which service should assess it and how soon. If the person taking the message cannot advise, request clinical triage. Keep the agreed next step in writing so that “I reported it” does not become a substitute for knowing what happens next.

What VHL means, and which organs it can affect

The VHL gene helps make a protein involved in controlling how cells respond to oxygen availability. It acts as a tumor suppressor, helping restrain inappropriate cell growth. A disease-causing change can disrupt that control. This is a biological explanation for susceptibility, not evidence that a person caused the condition through something they ate or did. Changes in the VHL gene can also arise within an individual tumor in someone without hereditary VHL. Finding the gene’s name on a tumor report therefore does not, by itself, settle whether the person has an inherited syndrome; the clinical and genetics teams interpret the type of testing and its context. [4]

Inheritance is a probability, not a prediction of severity

VHL follows an autosomal dominant inheritance pattern. A parent with a disease-causing VHL variant has a 50% chance of passing it on in each pregnancy, regardless of the child’s sex. One child’s result does not change the probability for a later pregnancy. Some people have a new variant without an affected parent. Relatives who inherit the same variant can still develop different manifestations at different ages, so one family member’s experience cannot reliably forecast another’s course. [1]

For a family discussion, distinguish “the chance of inheriting the variant” from “what life would look like if it were inherited.” The first is a genetic probability; the second requires an individual conversation. Avoid describing a relative as having a mild or severe future based only on an older family member’s history. A more useful shared document lists confirmed findings, unanswered questions, and the next opportunity to discuss them with the genetics team. [2]

How VHL is diagnosed and what genetic results mean

Clinicians may diagnose VHL using characteristic clinical findings and family history, or confirm it through an appropriate molecular test identifying a pathogenic or likely pathogenic VHL variant. The interpretation depends on the whole picture. A variant of uncertain significance, often shortened to VUS, does not establish or rule out VHL. A specialist may investigate further when the findings suggest VHL even if initial testing has not provided a clear molecular answer. Ask whether your diagnosis is clinically established, genetically confirmed, still under investigation, or a combination of these descriptions. [3]

A negative genetic result needs a precise explanation. If a family already has an identified disease-causing variant and an appropriate test shows that you did not inherit it, that can be an informative, or true, negative result. A negative result without an established family variant may be uninformative: it does not necessarily explain the family’s medical history or remove the need for follow-up based on that history. A positive pathogenic result is different from a VUS, where evidence remains insufficient. [5]

Ask for the actual laboratory report and a plain-language interpretation. Check who will notify you if an uncertain variant is reclassified and whether you need to update the clinic when family history changes. Do not cancel planned care simply because a portal displays “negative,” and do not treat an uncertain result as a confirmed harmful variant. The testing team can explain whether additional testing would answer a meaningful question. [5]

Preparing for a genetics appointment

Genetic counseling brings together your medical history, family history, testing options, and the implications of possible results. Before the visit, collect what you know about relatives’ diagnoses and the ages when they occurred. Bring copies of relevant reports if available, while being clear about information that is secondhand or uncertain. It is reasonable to arrive with unanswered questions; you do not need a complete family tree to ask for help. [6]

You can also ask about the emotional and practical implications of testing: how results will be explained, what relatives may want to discuss with their own clinicians, and how the information affects decisions that matter to you. A counselor’s role includes helping people understand choices and adapt to genetic risk. Write down your priorities before the appointment, especially if family planning, a child’s testing, or uncertainty about an existing result is the main reason for attending. [6]

Why each organ needs its own assessment

Eyes: protect vision before a change becomes obvious

The ocular VHL consensus guideline supports lifelong eye surveillance beginning in infancy for people with known or suspected VHL. A specialist examination is not the same as a routine check of how clearly you can read an eye chart. The aim is to identify retinal hemangioblastomas and decide whether treatment is needed before avoidable damage occurs. The guideline emphasizes clinicians experienced with these lesions and coordination with the wider VHL team. [8]

Treatment decisions depend on where a retinal lesion sits and what can be treated safely. The guideline supports early treatment of appropriate lesions, rather than waiting for every lesion to cause symptoms. It also acknowledges that much of the evidence comes from observational research rather than controlled trials. Ask the ophthalmologist what was seen, whether photography or other testing will help compare future examinations, and what specific change should trigger an earlier visit. [8]

Brain and spinal cord: benign does not mean harmless

Central nervous system hemangioblastomas are generally benign tumors, but they can still cause serious neurological harm. “Benign” describes their cancer behavior; it does not guarantee that their effects are minor or that monitoring is unnecessary. The CNS consensus statement supports clinical assessment alongside MRI surveillance, with earlier investigation when neurological signs or symptoms appear. It is therefore important to distinguish a scheduled screening scan from an assessment prompted by a new problem. [9]

When discussing a brain or spine finding, ask the clinician to identify its exact location and explain how the scan relates to your symptoms and examination. Ask whether the recommended next step is repeat imaging, another assessment, or treatment discussion, and who owns that decision. The purpose of surveillance is to detect important changes early; the existence of a scan date should not discourage you from reporting a change before that date. [9]

Kidneys: balance cancer control and kidney function

A kidney mass is assessed using its imaging appearance, size, growth over time, and the person’s other medical circumstances. VHL renal guidance supports active surveillance for selected small localized masses and evaluation for kidney-preserving surgery when intervention is appropriate. Active surveillance is a structured plan, with repeat assessment and criteria for changing course. It is not a declaration that a mass can never cause harm. [10]

Ask the urology team which finding is being followed, how the current scan compares with previous images, and what would change the recommendation. Preserving functioning kidney tissue matters when repeated kidney treatment may be needed. The best procedure for one mass is not automatically the best choice for another. A size threshold discussed for kidney tumors should not be applied to a retinal, brain, adrenal, or pancreatic lesion; those decisions use different clinical considerations. [10]

Inner ear: hearing and balance deserve a separate conversation

The endolymphatic sac tumor consensus statement places assessment of hearing and balance symptoms at the center of screening. This is a reason to mention changes in hearing, ringing, or balance explicitly rather than assuming that a general follow-up visit will cover them. Ask whether your plan includes a hearing assessment and what additional evaluation is appropriate for a new symptom. The clinician may coordinate ear-specialist assessment and imaging according to the findings. [11]

For an appointment, note which ear is affected, whether the change was sudden or gradual, and whether it fluctuates. Describe what you cannot hear or do as well as naming the symptom. This practical record can help frame the discussion, but it does not diagnose an endolymphatic sac tumor. Prompt assessment matters because preserving function is an important goal of identifying these lesions. [11]

Adrenal tumors: hormone effects can matter before surgery

Pheochromocytomas and related paragangliomas may release hormones that cause high blood pressure, headache, heavy sweating, shakiness, or a fast or irregular heartbeat. Other conditions can cause similar symptoms, and some tumors cause no obvious symptoms. Evaluation can include blood or urine testing and imaging. A blood pressure reading alone cannot provide the complete assessment. [12]

Tell the team about a known or suspected hormone-producing tumor before an operation, anesthesia, or another planned procedure. Surgery and anesthesia can provoke dangerous hormone-related effects. Specialists may prescribe medication to control blood pressure and heart rate before tumor surgery. This preparation is part of treatment, not a step to skip because an operation is already booked. Do not start, stop, or rearrange these medicines from a general article; ask the endocrinology and surgical teams to give you a coordinated written plan. [12]

Pancreas: a precise name matters

When a pancreatic neuroendocrine tumor is identified, decisions depend on features such as its type, hormone production, size, location, stage, and grade. These tumors need their own treatment discussion. NCI describes active surveillance for selected small or low-grade tumors and surgery or other treatments for different circumstances. A general pancreatic cancer treatment page or another patient’s regimen may not describe the type of lesion you have. [13]

Ask whether the finding is being watched because it is currently suitable for surveillance, whether more characterization is needed, or whether treatment is being recommended. If surgery is proposed, ask which part of the pancreas would be affected and what follow-up would be needed. If medicine is proposed, ask what response the team hopes to see and how it will be measured. Follow-up testing is part of deciding whether a treatment is helping or whether the plan should change. [13]

Build a surveillance plan you can actually follow

VHL surveillance begins in childhood for people with the condition or at risk of it and covers multiple organ systems. An evidence-based guideline identifies the retina, central nervous system, inner ear, kidneys, neuroendocrine glands, and pancreas as areas requiring attention. Treatment is planned to address disease while avoiding unnecessary harm. These aims explain why the plan is broader than a single scan or an annual blood test. [7]

The right schedule is individualized by clinicians familiar with VHL. Your age, findings, symptoms, and treatment history need to be considered when translating guidance into appointments. A new lesion may require its own follow-up even while other organs remain on a screening schedule. Ask for the version of the plan that applies to you now, including who can change it. Do not copy a relative’s calendar or use a general internet table as permission to delay an assessment. [7]

Prepare safely for MRI appointments

MRI uses strong magnetic fields, so the imaging team needs accurate information about implanted devices, pumps, clips, metal fragments, and previous procedures. Bring device information if you have it and complete screening even if you have had an MRI before. Staff must determine whether a device is compatible with the particular scan and conditions. Do not assume that an item is safe merely because it was allowed at another appointment. [22]

Also disclose kidney disease, prior reactions to MRI contrast, and pregnancy or possible pregnancy before the examination. Some MRI studies use gadolinium contrast; the radiology team weighs the benefits and precautions for your situation. Raise claustrophobia or difficulty lying still when booking so staff can discuss arrangements. Do not cancel needed imaging or change the prescribed scan yourself because of a generalized warning online. Ask the ordering clinician and radiology service to resolve the specific concern. [22]

Making treatment decisions without losing sight of the goal

Before agreeing to a treatment, ask what problem it is intended to solve, what benefit is realistic, and what important risks or lasting effects it carries. Ask about alternatives, including when observation is appropriate, and how urgently the decision must be made. Clarify the practical demands: time away from work, recovery, help at home, follow-up visits, and whom to call with side effects. These questions help turn a treatment name into an understandable choice. [24]

It is also reasonable to ask for a second opinion and copies of the records needed for it. If specialists recommend different options, ask them to explain the assumptions behind each recommendation. The useful comparison is the expected benefit and harm for your particular finding and circumstances. Ask what remains uncertain and which information, if obtained, could change the decision. [24]

A short decision sheet can help: “The decision is ___; the options discussed are ___; my main concern is ___; the question I still need answered is ___.” Bring it back to the clinician rather than trying to settle unanswered medical questions alone. If the plan changes, keep the earlier version with its date so you can understand what new information led to the change.

Belzutifan: an important option with specific limits

Under the U.S. prescribing information revised September 2026, belzutifan, marketed as WELIREG, is indicated for adults with VHL who need therapy for associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors, when immediate surgery is not required. It is not an automatic treatment for every VHL finding. [14]

Important risks include anemia and low oxygen levels, requiring checks before and during treatment. Report breathing problems promptly. The boxed warning addresses fetal harm: pregnancy testing and effective non-hormonal contraception are needed for patients who can become pregnant, because some hormonal contraceptives can become less effective. Male patients with partners who could become pregnant also need effective contraception. The label advises against breastfeeding and warns of possible fertility impairment. Ask for the appropriate precautions and duration for your actual regimen. Have a pharmacist review prescription medicines, over-the-counter products, and supplements for interactions; the team may need to interrupt, reduce, or stop treatment for toxicity. [14]

The newer PPGL approval is a different indication

In May 2025, the FDA separately approved belzutifan for adults and children aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma. That approval does not make the VHL-specific indication a general pediatric indication, and it does not mean every adrenal tumor should receive the medicine. Ask which exact diagnosis and indication apply to the proposed prescription. An age mentioned in one approval should not be transferred to another without checking its wording. [15]

What a response in a study can, and cannot, tell you

The original 2021 VHL belzutifan trial was a phase 2, open-label study in which all participants received the drug; it did not randomly compare the medicine with surgery or observation. Researchers assessed tumor response using defined imaging criteria. The study showed activity against VHL-associated tumors, an important development, but its design does not establish that the medicine is the best option for every person or every lesion. [16]

A measured tumor response is not the same as eliminating the inherited predisposition. When discussing research results, ask which outcome is being reported: shrinkage on imaging, control over time, symptoms, or another measure. Also ask how closely the study population resembles your situation. A treatment discussion should connect the evidence to your goals and to the trade-offs your team is considering, rather than relying on a headline response percentage alone. [16]

Before starting an oral treatment, request a written contact plan: where laboratory checks happen, who reviews them, where you report a new symptom, and what to do if you cannot reach the usual clinic. Confirm how refills are arranged and whether an upcoming trip changes the logistics. Keep the current prescription instructions with your medicines rather than relying on an old clinic letter or a remembered dose.

Kidney cysts do not all mean the same thing

Simple kidney cysts are common and are often found accidentally during imaging for another reason. Their usual behavior differs from inherited cystic kidney disorders. A report’s description matters: “simple cyst” is a characterization, not a synonym for every kidney mass. Ask the clinician what type of finding was seen and whether it changes your existing plan. General advice that an ordinary simple cyst needs no treatment should not be used to interpret an unspecified lesion without the actual imaging assessment. [20]

Autosomal dominant polycystic kidney disease, or ADPKD, is a separate inherited condition, usually associated with PKD1 or PKD2. Sharing the words “autosomal dominant” or having kidney cysts does not make it the same diagnosis as VHL. Our ADPKD patient guide provides related reading about that different condition. Its monitoring and treatment advice does not replace a VHL plan; use the diagnosis established by your own team when deciding which information is relevant. [21]

After removal of a kidney

If treatment leaves you with one functioning kidney, follow-up includes kidney function and blood pressure, not only checking for tumors. NIDDK describes blood testing of filtration and urine testing for albumin as ways to assess kidney health. Tell health professionals about the solitary kidney before new medicines or procedures. Ask how kidney monitoring fits alongside your specialist follow-up so that responsibility is clear. [23]

Having one kidney does not automatically require a special diet, but reduced kidney function may change nutritional advice. A clinician or dietitian can tailor a plan to your results and needs. Discuss activity and injury risks in context rather than imposing blanket restrictions yourself. Keep a current medication list and ask about the safety of nonprescription products before using them; protecting remaining kidney function deserves its own explicit place in the care plan. [23]

Children, family planning, and changing life stages

When a family’s disease-causing VHL variant is known, testing of at-risk relatives, prenatal testing, and preimplantation genetic testing may be possible. These are personal choices to discuss with genetics and reproductive specialists. The best time to explore reproductive options is before pregnancy when possible. Counseling can address available approaches without assuming that everyone wants testing, pregnancy, or the same way of building a family. [3]

If pregnancy is planned or has begun, involve the VHL team early. Pregnancy care may require closer attention to existing manifestations and screening for pheochromocytoma. Ask who will coordinate specialist surveillance with obstetric care, rather than assuming that routine pregnancy appointments cover VHL-specific concerns. [3]

For someone who may want a future pregnancy, discuss fertility before starting treatment that could affect it. NCI recommends asking how the proposed therapy may affect reproductive function and whether referral to a fertility specialist is appropriate. Available preservation approaches, their timing, and their practical demands differ. A fertility discussion is not a reason to postpone necessary treatment independently; the treating team and fertility specialist should address timing together. [28]

Be clear about what you want to understand: the effect of treatment on fertility, options to preserve fertility, the safety of a future pregnancy, or the chance of passing on a genetic variant. These questions overlap but require different expertise. You can ask for information even if you have not decided whether you want children. Knowing the options can support a later choice without committing you to a procedure now. [28]

For a child or teenager, make the appointment plan understandable in age-appropriate language. A practical family checklist can include who books visits, who receives results, and who will help explain changes. As a young person takes more responsibility, involve them in asking questions and keeping contact details. Before changing hospitals or moving away, ask the current clinic for a written handover and confirm that the receiving service has accepted the referral.

Coordinating care and living with uncertainty

A published VHL care pathway was developed with medical specialists, specialized nurses, and patient representatives to help organize care across disciplines. Its central practical lesson is that expertise needs coordination. The clinicians addressing individual organs should contribute to an overall plan, rather than leaving the patient to resolve every overlap. Ask whether your service has a named coordinating clinician, specialist nurse, or comparable contact who can help connect the pieces. [27]

When several services are involved, clarify which team is responsible for each follow-up and who should receive outside results. Integrated care can be organized through an expert center working with local services; it need not mean every conversation occurs with the same person. Ask how recommendations are reconciled when different specialties are considering procedures or medicines at the same time. The care pathway is a framework for organizing that collaboration, not a promise that every clinic has identical resources. [27]

The uncertainty around repeated tests, treatment decisions, or a cancer diagnosis can bring worry, anger, sadness, or a sense of lost control. NCI’s coping guidance encourages discussing difficult feelings and using support from health professionals, trusted people, or support groups. These resources may be helpful when navigating VHL, even though not every person with VHL has cancer. You do not need to describe yourself as coping badly to ask for support. [25]

Tell the team when distress is interfering with sleep, concentration, relationships, or daily activities. Ask about counseling or other appropriate help. Different people want different amounts of information and different kinds of company at appointments. It is reasonable to say what helps you: a written summary, someone taking notes, time to process results, or an explanation repeated in simpler language. Support should reflect your needs rather than an expectation to remain positive at all times. [25]

Keep a compact record that you can share when needed: the confirmed diagnosis, relevant genetic report, major procedures, current medicines, allergies, specialist contacts, and the latest agreed plan. Store the detailed reports separately so the summary stays usable. Before travel or a move, check how to obtain records and how to reach the appropriate service. If cost, transport, language, or accessibility makes appointments difficult, name that barrier directly and ask what assistance is available.

Research, realistic expectations, and your next appointment

Clinical trials have specific eligibility requirements and a protocol describing what participants will do. A study listing is an invitation to investigate whether it fits, not a guarantee of entry or benefit. Before deciding, ask the research team to explain the purpose, expected visits and tests, possible risks, alternatives, and how research care connects with your usual clinicians. Make sure you understand which arrangements are research-specific and which remain part of ordinary care. [26]

Informed consent is a discussion, not just a signature. Ask questions about anything unclear, including time commitments, travel, insurance, and whom to contact if something goes wrong. Participation is voluntary, and you can leave a study. If you are considering withdrawal, discuss how to do so safely and what care comes next. Do not replace an established treatment plan with an unverified claim of a cure or assume that a promising research result already answers your own treatment question. [26]